Medical technology company Teleflex (NYSE:TFX) announced better-than-expected revenue in Q2 CY2025, with sales up 2.3% year on year to $780.9 million. Its non-GAAP profit of $3.73 per share was 10.8% ...

This medical technology company supplies single-use devices for critical care and surgery to hospitals and healthcare providers worldwide.

Acquisition will further advance Teleflex’s Interventional portfolio with a differentiated global suite of coronary vascular and peripheral vascular intervention devices WAYNE, Pa., Feb. 27, 2025 ...

Ratings for Teleflex (NYSE:TFX) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

Fintel reports that on January 27, 2026, Needham upgraded their outlook for Teleflex (NYSE:TFX) from Hold to Buy. Analyst ...

What recent performance says about Teleflex Teleflex (TFX) has drawn attention after a mixed stretch, with the stock up about ...

WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The ...

In early January 2026, Teleflex announced the past departure of Chairman, President and CEO Liam Kelly, appointed long-time director Stuart Randle as Interim President and CEO, named Dr. Stephen ...

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, ...

Look here for a clue. There's no foolproof way to know the future for Teleflex (NYSE: TFX) or any other company. However, certain clues may help you see potential stumbles before they happen -- and ...